Palacios J, Benito N, Pizarro A, Limeres M A, Suárez A, Cano A, Gamallo C
Departamento de Antomía Patológica, Hospital La Paz, Madrid, Spain.
Virchows Arch. 1995;427(3):259-63. doi: 10.1007/BF00203392.
A recent in vitro study has suggested that overexpression of ERBB2 may mediate breast tumour progression and metastasis by inhibiting the transcription of the E-cadherin (E-CD) gene. To test this hypothesis in human breast cancer in vivo, we studied the relationship between the expression of both molecules in 247 breast carcinomas immunohistochemically. Five ductal carcinomas in situ overexpressed ERBB2 and showed preserved E-CD expression. Forty-four of 226 infiltrating ductal carcinomas (19.47%) showed ERBB2 overexpression, and a statistically significant relationship was found between ERBB2 overexpression and high histological grade. E-CD expression was preserved in 111 cases (49.1%) and correlated with the histological grade. However, no significant relationship was found between ERBB2 and E-CD expression. None of the 16 infiltrating lobular carcinomas expressed ERBB2 or E-CD. These observations in different histological types of breast carcinoma strongly argue against a role for ERBB2 as a transcriptional regulator of E-CD expression in most human breast carcinomas in vivo.
最近的一项体外研究表明，ERBB2的过表达可能通过抑制E-钙黏蛋白（E-CD）基因的转录来介导乳腺肿瘤的进展和转移。为了在体内人类乳腺癌中验证这一假设，我们通过免疫组织化学研究了247例乳腺癌中这两种分子表达之间的关系。5例原位导管癌ERBB2过表达且E-CD表达保留。226例浸润性导管癌中有44例（19.47%）表现出ERBB2过表达，并且在ERBB2过表达与高组织学分级之间发现了具有统计学意义的关系。111例（49.1%）病例中E-CD表达保留，且与组织学分级相关。然而，未发现ERBB2与E-CD表达之间存在显著关系。16例浸润性小叶癌均未表达ERBB2或E-CD。在不同组织学类型的乳腺癌中的这些观察结果有力地反驳了在大多数体内人类乳腺癌中ERBB2作为E-CD表达的转录调节因子的作用。
